1. McNicholas, TA. Management of symptomatic BPH in the UK: who is treated and how? Eur Urol 1999; 36(Suppl. 3): 33–39.
Google Scholar | Crossref | Medline2. Van Asseldonk, B, Barkin, J, Elterman, DS, et al. Hyperplasia: a review. Curr Opin Oncol 2014; 23: 863–910.
Google Scholar3. Kawakami, J, Nickel, JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient’s perspective. Can J Urol 1999; 6: 819–822.
Google Scholar | Medline4. Worthington, J, Taylor, H, Abrams, P, et al. A randomised controlled trial to determine the clinical and cost effectiveness of thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP) in the National Health Service (NHS) – the UNBLOCS. Trials 2017; 18: 1–11.
Google Scholar | Crossref | Medline5. Malaeb, BS, Yu, X, McBean, AM, et al. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000–2008). Urology 2012; 79: 1111–1117.
Google Scholar | Crossref | Medline6. Hashim, H, Abrams, P. Transurethral resection of the prostate for benign prostatic obstruction: will it remain the gold standard? Eur Urol 2015; 67: 1097–1098.
Google Scholar | Crossref | Medline7. Ahyai, SA, Gilling, P, Kaplan, SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010; 58: 384–397.
Google Scholar | Crossref | Medline | ISI8. Mamoulakis, C, Ubbink, DT, de la Rosette, JJMCH. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol 2009; 56: 798–809.
Google Scholar | Crossref | Medline9. Kuntz, RM, Lehrich, K, Ahyai, SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008; 53: 160–168.
Google Scholar | Crossref | Medline | ISI10. British Association of Urological Surgeons (BAUS) . Transurethral prostatectomy (TURP) for benign disease. Information on your procedure by The British Association of Urological Surgeons (BAUS), https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/TURP for benign.pdf (2017, accessed 22 January 2020).
Google Scholar11. Urology EAO . EAU patient information: TURP, https://patients.uroweb.org/treatments/transurethral-resection-prostate-turp/ (2021, accessed 22 January 2020).
Google Scholar12. Hashim, H, Worthington, J, Abrams, P, et al. Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. Lancet 2020; 396: 50–61.
Google Scholar | Crossref | Medline13. Urolift . What is urolift? How does it work, https://www.urolift.com/what-is-urolift (2021, accessed 28 December 2020).
Google Scholar14. Gravas, S, Cornu, J, Gacci, M, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Eur Assoc Urol 2020: 36–37. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
Google Scholar15. Kellog Parsons, J, Dahm, P, Kohler, TS, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. Letter. J Urol 2021; 205: 938.
Google Scholar16. NICE . UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia, www.nice.org.uk/guidance/mtg26 (September 2020, accessed 28 December 2020).
Google Scholar17. Rukstalis, D, Grier, D, Stroup, SP, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis 2019; 22: 411–419.
Google Scholar | Crossref | Medline18. Roehrborn, CG, Barkin, J, Gange, SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017; 24: 8802–8813.
Google Scholar | Medline19. Gratzke, C, Barber, N, Speakman, MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 2017; 119: 767–775.
Google Scholar | Crossref | Medline20. Kayes, O, Page, T, Barber, N, et al. Prostatic urethral lift treatment in subjects with acute urinary retention (PULSAR). Gothenberg: International Continence Society, 2019.
Google Scholar21. Johnston, MJ, Hindley, RG. Rezum water vapour therapy for benign prostatic hyperplasia. Trends Urol Mens Health 2019; 10: 21–24.
Google Scholar | Crossref22. Mynderse, LA, Hanson, D, Robb, RA, et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 2015; 86: 122–127.
Google Scholar | Crossref | Medline23. McVary, KT, Rogers, T, Roehrborn, CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 2019; 126: 171–179.
Google Scholar | Crossref | Medline24. National Institute for Health and Clinical Excellence (NICE) . Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia, https://www.nice.org.uk/guidance/mtg49/resources/rezum-for-treating-lower-urinary-tract-symptoms-secondary-to-benign-prostatic-hyperplasia-pdf-64372064176069 (2020, accessed 28 December 2020).
Google Scholar25. McVary, KT, Holland, B, Beahrs, JR. Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2020; 23: 303–308.
Google Scholar | Crossref | Medline26. Maclean, D, Maher, B, Modi, S, et al. Prostate artery embolization: a new, minimally invasive treatment for lower urinary tract symptoms secondary to prostate enlargement. Ther Adv Urol 2017; 9: 2019–2216.
Google Scholar | SAGE Journals27. National Institute for Health and Clinical Excellence (NICE) . Prostate artery embolisation for benign prostatic hyperplasia. BMJ 2018; 361: k2537.
Google Scholar | Medline28. Gao, YA, Huang, Y, Zhang, R, et al. Benign Prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate-a prospective, randomized, and controlled clinical trial. Radiology 2014; 270: 920–928.
Google Scholar | Crossref | Medline | ISI29. Abt, D, Hechelhammer, L, Müllhaupt, G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 2018; 361: k2338.
Google Scholar | Crossref | Medline30. Carnevale, FC, Iscaife, A, Yoshinaga, EM, et al. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol 2016; 39: 44–52.
Google Scholar | Crossref | Medline | ISI31. Insausti, I, Sáez de Ocáriz, A, Galbete, A, et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 2020; 31: 882–890.
Google Scholar | Crossref | Medline32. Gondran-Tellier, B, McManus, R, Sichez, PC, et al. Efficacy and safety of surgery for benign prostatic obstruction in patients with preoperative urinary catheter. J Endourol 2021; 35: 102–108.
Google Scholar | Crossref | Medline33. Müllhaupt, G, Hechelhammer, L, Engeler, DS, et al. In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial. BJU Int 2019; 123: 1055–1060.
Google Scholar | Crossref | Medline34. Taktak, S, Jones, P, Haq, A, et al. Aquablation: a novel and minimally invasive surgery for benign prostate enlargement. Ther Adv Urol 2018; 10: 183–188.
Google Scholar | SAGE Journals | ISI35. Gilling, P, Barber, N, Bidair, M, et al. WATER: a double-blind, randomized, controlled trial of aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 2018; 199: 1252–1261.
Google Scholar | Crossref | Medline36. NICE . Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia [Internet], https://www.nice.org.uk/guidance/ipg629/resources/transurethral-water-jet-ablation-for-lower-urinary-tract-symptoms-caused-by-benign-prostatic-hyperplasia-pdf-1899873991040965 (2018, accessed 28 December 2020).
Google Scholar37. Gilling, P, Barber, N, Bidair, M, et al. Two-year outcomes after aquablation compared to TURP: efficacy and ejaculatory improvements sustained. Adv Ther 2019; 36: 1326–1336.
Google Scholar | Crossref | Medline38. Nguyen, DD, Barber, N, Bidair, M, et al. WATER versus WATER II 2-year update: comparing aquablation therapy for benign prostatic hyperplasia in 30–80-cm3 and 80–150-cm3 prostates. Eur Urol 2021; 25: 21–28.
Google Scholar39. Yee, C-H, Ng, CF, Chiu, PKF, et al. Efficacy of aquablation in patients with urinary retention. Eur Urol Open Sci 2020; 19: e2430.
Google Scholar | Crossref40. Balakrishnan, D, Jones, P, Somani, BK. iTIND: the second-generation temporary implantable nitinol device for minimally invasive treatment of benign prostatic hyperplasia. Ther Adv Urol 2020; 12: 1–5.
Google Scholar | SAGE Journals41. Porpiglia, F, Fiori, C, Amparore, D, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int 2019; 123: 1061–1069.
Google Scholar | Crossref | Medline42. Chughtai, B, Elterman, D, Shore, N, et al. The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, randomized, controlled trial. Urology. Epub ahead of print 26 December 2020. DOI: 10.1016/j.urology.2020.12.022.
Google Scholar | Crossref43. Speakman, MJ, Cornu, JN, Gacci, M, et al. What is the required certainty of evidence for the implementation of novel techniques for the treatment of benign prostatic obstruction? Eur Urol Focus 2019; 5: 351–356.
Google Scholar | Crossref | Medline44. MEQnordic . MEQnordic: urolift, https://meqnordic.com/products/urology/urolift.aspx (2021, accessed 8 April 2021).
Google Scholar45. Bollinger, J. Chester County Robotic Surgery [Internet], https://chestercountyroboticsurgery.com/services-procedures/rezum-bph-treatment (2019, accessed 8 April 2021).
Google Scholar46. Boston Scientific . What is Rezum, https://www.bostonscientific.com/en-EU/products/lithotripsy/rezum-water-vapor-therapy.html (2021, accessed 8 April 2021).
Google Scholar47. Desert Vein and Vascular . Desertveinandvascular: prostate artery embolization (PAE): treatment for benign prostatic hyperplasia, https://www.desertveinandvascular.com/prostate-artery-embolization-pae-treatment-for-benign-prostatic-hyperplasia/ (2021, accessed 8 April 2021).
Google Scholar48. Kumar, P, Ravi, SSR. Prostate artery embolisation: technique. Urol News 2016; 20.
Google Scholar49. Faber, K, De Abreu, ALC, Ramos, P, et al. Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol 2015; 29: 63–69.
Google Scholar | Crossref | Medline50. Olymous . Olympus: iTind, https://www.olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html (2021, accessed 8 April 2021).
Google Scholar